Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

Since its initial approval for moderate-to-severe atopic dermatitis, Dupixent has secured approvals across eight other diseases, including severe chronic rhinosinusitis with nasal polyposis, severe ...

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data ...
Zacks Investment Research on MSN

Kymera jumps 17% on early enrollment completion in skin disease study

Kymera Therapeutics KYMR shares surged 16.6% on Thursday after announcing enrollment completion in the global phase IIb ...
The Globe and Mail

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth in the first quarter because investors are increasingly focused on its long-term ...
oncnursingnews

Managing Adverse Reactions to Help Optimize Outcomes in Certain Urothelial Cancers

PADCEV (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly ...

New expert recommendations aim to improve detection and care of lung disease in people with rheumatoid arthritis

A new international expert consensus statement published in The Lancet Respiratory Medicine provides guidance for doctors on ...
American Lung Association

World Bronchiectasis Day: 3 Things to Know About the Irreversible Lung Disease that Impacts 500,000 People in the U.S.

Today is World Bronchiectasis Day, an observance to raise awareness about a lesser-known chronic lung disease that affects between 350,000 and 500,000 adults in the United States. To educate adults ...

As the temperature rises, so do the risks for people living with interstitial lung disease

People living with interstitial lung disease (ILD) are especially vulnerable during extreme heat. As climate change drives more frequent and intense heatwaves, people with ILD will need better ...

The remarkable life story behind America’s last iron lung user

Martha Ann Lillard, the last known person in the United States to rely on an iron lung after surviving polio, has died at age ...

Airway cells, not immune cells, trigger silicosis: New understanding of a deadly disease

Silicosis—a devastating, incurable lung disease caused by inhaling silica dust—is surging worldwide, fueled by a new wave of ...

Martha Lillard, last US polio patient using iron lung, dies at 78 in Oklahoma

Martha Lillard, the last U.S. polio patient using an iron lung, has died at 78 in Oklahoma. Her sister, Cindy McVey, ...
The Hindu

Woman with rheumatoid arthritis-associated interstitial lung disease breathes easy with lungs from teenager

A 39-year-old homemaker from West Bengal, who was suffering from rheumatoid arthritis-associated interstitial lung disease, now breathes easier with the lungs of a teenager. The progressive condition ...